GSK extends emerging markets business
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.GlaxoSmithKline continued its march into the emerging markets by taking a 9.9 per cent in a South Korean drugs group yesterday. Europe's largest pharmaceuticals company said that it had entered into a strategic alliance with Dong-A Pharmaceuticals, paying £73.9m for its stake in the company.
The alliance will initially co-promote a number of GSK and Dong-A products for use in primary care. The two companies said that additional synergies will be explored to strengthen both companies' commercial positions within the Korean market. Under the deal, the companies will share profits generated from the co-promoted products.
"With Dong-A's market-leading position and expertise in Korea, this alliance presents a significant opportunity for GSK to extend its commercial footprint and build operational scale in this fast growing Asian market," said Christophe Weber of GSK's Asia-Pacific region.
The deal is typical of the kind of transaction favoured by GSK since Andrew Witty became chief executive two years ago. The group has cut spending on research and development and has switched its attention away from high-cost medicines in favour of activity in developing economies. In addition to yesterday's deal, GSK has similar deals in a number of countries, including South Africa.
Separately, maker of diagnostic tests Response Genetics signed a deal with GSK yesterday, giving the pharma giant the tests which assess gene mutilations.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments